- Moving toward hepatitis B virus functional cure - the impact of on-treatment kinetics of serum viral markers
-
Liang LY, Wong VWS, Wong GLH, Yip TCF
- KMID: 2538207
- Clin Mol Hepatol.
- 2023 Jan;29(1):113-117.
- doi: 10.3350/cmh.2022.0333
-
- CITED
-
- Close
- SHARE
-
- Close
- Negligible risk of hepatocellular carcinoma in chronic hepatitis B patients in immune-tolerant phase: Myth or fact
-
Yip TCF, Wong GLH, Wong VWS
- KMID: 2514767
- Clin Mol Hepatol.
- 2021 Apr;27(2):273-277.
- doi: 10.3350/cmh.2021.0019
-
- CITED
-
- Close
- SHARE
-
- Close
- Drug-drug interactions with direct-acting antivirals — less is more
-
Wong GLH
- KMID: 2511452
- Clin Mol Hepatol.
- 2021 Jan;27(1):81-82.
- doi: 10.3350/cmh.2020.0278
-
- CITED
-
- Close
- SHARE
-
- Close
- Application of transient elastography in nonalcoholicfatty liver disease
-
Zhang X, Wong GLH, Wong VWS
- KMID: 2500376
- Clin Mol Hepatol.
- 2020 Apr;26(2):128-141.
- doi: 10.3350/cmh.2019.0001n
Nonalcoholic fatty liver disease (NAFLD) is currently the most common chronic liver disease worldwide. Although it has become one of the leading causes of cirrhosis and hepatocellular carcinoma in the... -
- CITED
-
- Close
- SHARE
-
- Close
- Non-invasive biomarkers for liver inflammation in non-alcoholic fatty liver disease: present and future
-
Yip TCF, Lyu F, Lin H, Li G, Yuen PC, Wong VWS, Wong GLH
- KMID: 2539799
- Clin Mol Hepatol.
- 2023 Feb;29(Suppl):S171-S183.
- doi: 10.3350/cmh.2022.0426
Inflammation is the key driver of liver fibrosis progression in non-alcoholic fatty liver disease (NAFLD). Unfortunately, it is often challenging to assess inflammation in NAFLD due to its dynamic nature... -
- CITED
-
- Close
- SHARE
-
- Close
- Serum fibrosis index-based risk score predicts hepatocellular carcinoma in untreated patients with chronic hepatitis B
-
Liang LY, Lee HW, Wong VWS, Yip TCF, Tse YK, Hui VWK, Lui GCY, Chan HLY, Wong GLH
- KMID: 2517633
- Clin Mol Hepatol.
- 2021 Jul;27(3):499-509.
- doi: 10.3350/cmh.2020.0333
Background/Aims: Serum fibrosis scores comprised of common laboratory tests have high utility to assess severity of liver fibrosis. We aimed to derive and validate a hepatocellular carcinoma (HCC) risk score... -
- CITED
-
- Close
- SHARE
-
- Close
- U-shaped relationship between urea level and hepatic decompensation in chronic liver diseases
-
Lin H, Wong GLH, Zhang X, Yip TCF, Liu K, Tse YK, Hui VWK, Lai JCT, Chan HLY, Wong VWS
- KMID: 2523873
- Clin Mol Hepatol.
- 2022 Jan;28(1):77-90.
- doi: 10.3350/cmh.2021.0188
Background/Aims: We aimed to determine the association between blood urea level and incident cirrhosis, hepatic decompensation, and hepatocellular carcinoma in chronic liver disease (CLD) patients. Methods: The association between blood urea... -
- CITED
-
- Close
- SHARE
-
- Close
- Use of glecaprevir/pibrentasvir in patients with chronic hepatitis C virus infection and severe renal impairment
-
Yap DYH, Liu KSH, Hsu YC, Wong GLH, Tsai MC, Chen CH, Hsu CS, Hui YT, Li MKK, Liu CH, Kan YM, Yu ML, Yuen MF
- KMID: 2507974
- Clin Mol Hepatol.
- 2020 Oct;26(4):554-561.
- doi: 10.3350/cmh.2020.0058
Background/Aims: Data on treatment efficacy and safety of glecaprevir/pibrentasvir (GLE/PIB) for chronic hepatitis C virus (HCV) infection in Asian patients with severe renal impairment are limited. This study aimed to... -
- CITED
-
- Close
- SHARE
-
- Close
